MedTrace Logo

Low-dose Cortisol in Chronic Posttraumatic Stress Disorder

NCT00362661 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-01-12

No results posted yet for this study

Summary

The aim of this prospective, double-blind, placebo-controlled, cross-over study is to determine the therapeutic efficacy of low-dose cortisol for symptoms of chronic posttraumatic stress disorder.

Conditions

Interventions

DRUG

Cortisol

Cortisol 10 mg/d for 3 months

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Dominique de Quervain, MD · Division of Psychiatry Research, University of Zurich, Lenggstr. 31, 8032 Zurich, Switzerland

  • Ulrich Schnyder, MD · Department of Psychiatry, University Hospital Zurich, Culmannstrasse 8, 8091 Zürich, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00362661 on ClinicalTrials.gov